Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24656226 | 0.89 | MAPK1 (0.52) | MAPK1SMN1; SMN2MAPTRAB9AHCRTR1 | |
| SCHEMBL26527678 | 0.87 | RAB9A (0.51) | MAPK1SMN1; SMN2MAPTRAB9AHCRTR1 | |
| SCHEMBL1768201 | 0.86 | RAB9A (0.69) | MAPK1SMN1; SMN2MAPTRAB9AHCRTR1 | |
| SCHEMBL4803580 | 0.83 | MAPK1 (0.64) | MAPK1SMN1; SMN2MAPTRAB9AHCRTR1 | |
| SCHEMBL16447604 | 0.81 | SMN1; SMN2 (0.46) | MAPK1SMN1; SMN2MAPTRAB9ANPC1 | |
| SCHEMBL12295210 | 0.81 | MAPK1 (0.68) | MAPK1SMN1; SMN2MAPTRAB9AHCRTR1 | |
| SCHEMBL15767331 | 0.79 | PDE4A (0.53) | MAPK1SMN1; SMN2RAB9ANPC1KMT2A | |
| SCHEMBL2829842 | 0.79 | MAPK1 (1.00) | MAPK1SMN1; SMN2MAPTRAB9AHCRTR1 | |
| Potassium Ion SCHEMBL21818304 | 0.79 | GAA (0.45) | MAPK1SMN1; SMN2MAPTRAB9ANPC1 | |
| SCHEMBL19723803 | 0.78 | MAPT (0.50) | MAPK1SMN1; SMN2MAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| CN-113164459-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20200102303-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
| US-20160185774-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2016-06-30 | — | — | US | disclosed |
| US-20160185774-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2016-06-30 | — | — | US | disclosed |
| WO-2015014993-A2 | ANTI-INFECTIVE COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2015-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | MAPK1 4389/4885SMN1; SMN2 3418/4885MAPT 2516/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | MAPK1 4010/4885SMN1; SMN2 3345/4885MAPT 3782/4885 |
| US-20200102303-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | MAPK1 4389/4885SMN1; SMN2 3418/4885MAPT 2516/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | MAPK1 4389/4885SMN1; SMN2 3418/4885MAPT 2516/4885 |
| US-20160185774-A1 | Anti-Infective Compounds | RABGGTB, ELANE, SERPINB1 | MAPK1 1956/4885SMN1; SMN2 4839/4885MAPT 2660/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | MAPK1 4389/4885SMN1; SMN2 3418/4885MAPT 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.